An observational study in Stroke, sponsored by Shirley Ryan AbilityLab. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Shirley Ryan AbilityLab · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Stroke by Shirley Ryan AbilityLab — 12 open to participants now, 20 under way, none of them phase 3. Stroke · Shirley Ryan AbilityLab.
Among the 64 studies in Stroke by Shirley Ryan AbilityLab, this one is one of 6 that started in 2017, is one of 9 observational ones, reaches primary completion later than 16 of the 19 other live ones, and was the 29th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →12 of the 64 studies in Stroke by Shirley Ryan AbilityLab are open now, in 1 country. Recruiting first, the newest first:
Shirley Ryan AbilityLab · Sites in United States
Ages 18+
Shirley Ryan AbilityLab · Sites in United States
Ages 40–70 · Healthy volunteers
Shirley Ryan AbilityLab · Sites in United States
Ages 18+ · Healthy volunteers
Shirley Ryan AbilityLab · Sites in United States
Ages 18+
Shirley Ryan AbilityLab · Sites in United States
Ages 18–89
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 2
First in 2003; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 30 across the 55 interventional studies, 40 across the 9 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shirley Ryan AbilityLab is the lead sponsor of 181 studies on the registry; 44 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
7 of the studies in Stroke by Shirley Ryan AbilityLab that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03300141Shirley Ryan AbilityLabLooking Glass: Bimanual Balanced Reaching With Visual Biofeedback | 2026-12 |
| NCT05076565Shirley Ryan AbilityLabWearable Airbag Technology to Mitigate Falls in Individuals With High Fall Risk | 2026-12-14 |
| NCT05471375Shirley Ryan AbilityLabC-STAR Movement Database | 2026-12-31 |
| NCT06234124Shirley Ryan AbilityLabCharacterization and Clinical Trial of a Variable Friction Shoe | 2027-01 |
| NCT06663501Shirley Ryan AbilityLabEffects of Vibration on Motor Function of Survivors of Chronic Stroke | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Stroke by Shirley Ryan AbilityLab, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational trial seeks to assess the feasibility of using non-invasive, portable, real-time body-worn sensors to continuously monitor, quantify, and interpret recovery during inpatient treatment of stroke
OBJECTIVES:
Aim 1: Assess the feasibility of continuous long-term monitoring of inpatients with stroke using wearable sensors.
The investigators will obtain quantitative health data from research-grade, wireless, wearable sensors on individuals with subacute and chronic stroke in the clinical setting, as well as healthy controls.
The investigators will specifically check for variability in device data, as well as consistency and periodicity of sensor readings across the clinical study period. The investigators will analyze test-retest reliability and inter-rater reliability of using the wearable sensor technology for clinical and monitoring applications. Furthermore, The investigators will determine whether the sensors can distinguish biometric and activity characteristics between healthy controls and individuals with stroke.
Aim 2: Quantify upper and lower extremity movement impairments, mobility-related activities, speech and swallowing activities, and clinical parameters during stroke recovery.
The investigators will obtain continuous biometric and movement-based sensor data for clinical symptoms (e.g., muscle activation, heart rate variability, talk time, and gait quality) during the performance of validated clinical tests and during general inpatient activities (e.g., therapy, eating, and sleeping).
The investigators will compare device data with clinically validated measures of movement and language function, such as the Modified Ashworth Scale or Western Aphasia Battery. The investigators will describe variation of device data in subgroups of subjects defined by clinician assessed clinically validated measures (10-Meter Walk Test, Mini-Mental Status Exam, etc.). The investigators will also assess the ability of the sensors to capture response to treatment, such as movement therapy, speech therapy, medication, and Botox by comparing sensor data before and after treatment. The investigators will provide evidence about the degree to which the measured variables are intercorrelated. Lastly, The investigators will evaluate and compare the state of recovery between patients at time of discharge using sensor-based outcomes. Due to heterogeneity of clinical symptoms after stroke, as differing etiologies and degrees of recovery result in different types and levels of gait impairments, preliminary analyses may be performed on specific sub-datasets to determine which predictors, data types, and other data compositions affect algorithm performance before their application and evaluation on the dataset collected at the end of this study. Sub-datasets may be sampled based on (but not limited to) the population characteristics, the sensors used, the data available at the time analysis.
The patient cohort will consist of stroke survivors both admitted as inpatients to the Shirley Ryan AbilityLab and individuals in the community who had a stroke. The healthy control cohort will be recruited from the community sample.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient group
Healthy control group
Exclusion Criteria:
Patient group
Healthy control group
Individuals diagnosed with stroke admitted to the Shirley Ryan AbilityLab (inpatient), or individuals in the community who had a stroke (chronic)
Diagnostic Test: Wearable sensors
Individuals without any known significant health problems
Diagnostic Test: Wearable sensors
Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
Discharge clinical scores estimation
Error between clinical scores estimated from machine learning algorithms trained on sensor data from the Admission time-point, and true scores assessed at the discharge from the hospital.
Time frame: Discharge from inpatient stay. Average length of stay is 22 days.
Change in 6-Minute Walk Test (6MWT)
The 6MWT measures the distance a subject can walk indoors on a flat, hard surface in 6 minutes, using assistive devices as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The minimal detectable change for people with sub-acute stroke is 60.98 meters. Wearable sensors are used to monitor the movement of the subject during the test.
Time frame: From Admission time-point to 1-2 weeks, 1 month, 3 months, 6 months, 12 months post-stroke
Change in 10-Meter Walk Test (10MWT)
The 10MWT measures the amount of time it takes to walk 10 meters. Time will be recorded using a stopwatch and recorded to the one hundredth of a second. The effects of acceleration and deceleration are minimized by adding 1 meter at the beginning and end of the course to isolate the subject's steady state speed. The test will be recorded 3 times each at a normal self-selected pace and at a faster pace, with adequate rest in between. Results will be averaged from 3 trials. Any assistive devices or orthotics should be kept consistent throughout and documented. Wearable sensors are used to monitor the movement of the subject during the test.
Time frame: From Admission time-point to 1-2 weeks, 1 month, 3 months, 6 months, 12 months post-stroke
Change in Berg Balance Scale (BBS)
The BBS is a 14-item test, scored on a 5-level ordinal scale and validated against length of stay and discharge destination for stroke patients. The total score is expressed as a number between 0 and 56, where lower score mean increased balance impairment. It measures functional balance in a clinical setting during static and dynamic tasks (sitting, standing, transitioning from sit to stand, etc.). Wearable sensors are used to monitor the movement of the subject during the test.
Time frame: From Admission time-point to 1-2 weeks, 1 month, 3 months, 6 months, 12 months post-stroke
Change in Timed Up and Go (TUG)
The TUG assesses mobility by measuring the time a person take to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. It can detect longitudinal changes in mobility in stroke patients. The subject wears their routine footwear and orthotics and can use their mobility aids. Wearable sensors are used to monitor the movement of the subject during the test.
Time frame: From Admission time-point to 1-2 weeks, 1 month, 3 months, 6 months, 12 months post-stroke
Change in Functional Gait Assessment (FGA)
The FGA is comprised of 10-item that contains 7 of 8 items (except walking around obstacles) from the Dynamic Gait Index and 3 additional tasks, including walking with a narrow base of support, walking with the eyes closed, and walking backward. Subjects' performance of each test item was rated on a 4-point scale (0-3), with the total score ranging between 0 and 30. Wearable sensors are used to monitor the movement of the subject during the test.
Time frame: From Admission time-point to 1-2 weeks, 1 month, 3 months, 6 months, 12 months post-stroke
Change in Gait Analysis
Gait analysis provides a quantitative means of assessing walking function based on spatiotemporal parameters of gait. Subjects walk at both a comfortable and a fast pace over the GaitRite system, an electronic walkway with integrated sensors. Data from GaitRite is reliable and valid for evaluating walking characteristics and provides a gold standard for validating gait parameters from the sensors. Wearable sensors are used to monitor the movement of the subject during the test.
Time frame: From Admission time-point to 1-2 weeks, 1 month, 3 months, 6 months, 12 months post-stroke
Three months clinical score estimation
Error between clinical scores estimated from machine learning algorithms trained on sensor data from the Admission time-point, and true scores assessed at three months after the stroke event.
Time frame: 3 months after the stroke event
Six months clinical score estimation
Error between clinical scores estimated from machine learning algorithms trained on sensor data from the Admission time-point, and true scores assessed at six months after the stroke event.
Time frame: 6 months after the stroke event
Twelve months clinical score estimation
Error between clinical scores estimated from machine learning algorithms trained on sensor data from the Admission time-point, and true scores assessed at twelve months after the stroke event.
Time frame: 12 months after the stroke event
PDFs hosted by the registry, ClinicalTrials.gov.
Started Oct 2017 (actual). Primary completion is estimated for Dec 2027, 122 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.